The median follow-up after 42 months demonstrated that alectinib induces better results than crizotinib in ALK-inhibitor-naïve ALK-positive NSCLC patients, with a favorable safety profile (with incidences of TRAEs of 13.6% and 25.0%, respectively). The gene discussed is ALK; the disease is non-small cell lung carcinoma.